Publicacións nas que colabora con Urbano Anido Herranz (10)

2024

  1. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

2021

  1. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

    ESMO open, Vol. 6, Núm. 2, pp. 100090

2019

  1. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258

2018

  1. Abordaje del paciente con cáncer renal: ¿existe la colaboración entre urología y oncología?

    Actas Urologicas Espanolas

2017

  1. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, Núm. 7, pp. 1517-1522

  2. Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial

    European Journal of Cancer, Vol. 87, pp. 30-37

2016

  1. Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

    Current Oncology Reports, Vol. 18, Núm. 12

2013

  1. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 425-433

  2. Erratum: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor (Clinical and Translational Oncology DOI: 10.1007/s12094-012-0985-x)

    Clinical and Translational Oncology